BAYERCROP - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.2
| Stock Code | BAYERCROP | Market Cap | 19,730 Cr. | Current Price | 4,393 ₹ | High / Low | 6,540 ₹ |
| Stock P/E | 29.4 | Book Value | 695 ₹ | Dividend Yield | 2.84 % | ROCE | 24.8 % |
| ROE | 20.0 % | Face Value | 10.0 ₹ | DMA 50 | 4,575 ₹ | DMA 200 | 4,790 ₹ |
| Chg in FII Hold | 0.05 % | Chg in DII Hold | 0.42 % | PAT Qtr | 95.7 Cr. | PAT Prev Qtr | 153 Cr. |
| RSI | 38.7 | MACD | -99.8 | Volume | 13,446 | Avg Vol 1Wk | 16,296 |
| Low price | 4,273 ₹ | High price | 6,540 ₹ | PEG Ratio | -16.2 | Debt to equity | 0.03 |
| 52w Index | 5.29 % | Qtr Profit Var | 180 % | EPS | 149 ₹ | Industry PE | 24.1 |
📊 Financial Overview: Bayer CropScience (BAYERCROP) shows solid fundamentals with ROCE at 24.8% and ROE at 20.0%, reflecting strong efficiency. Debt-to-equity at 0.03 indicates a virtually debt-free balance sheet. Quarterly profit fell from ₹153 Cr. to ₹95.7 Cr., highlighting earnings volatility. Cash flows remain stable, but profit margins are under pressure.
💹 Valuation Indicators: The stock trades at a P/E of 29.4 compared to the industry average of 24.1, suggesting slight overvaluation. With a book value of ₹695, the P/B ratio is ~6.3, which is steep. PEG ratio of -16.2 signals weak growth prospects relative to valuation. Intrinsic value appears lower than the current market price of ₹4,393, making it moderately overvalued.
🏢 Business Model & Competitive Advantage: Bayer CropScience operates in the agrochemical and crop protection sector, leveraging strong R&D, global brand recognition, and diversified product offerings. Its competitive advantage lies in innovation, scale, and trusted brand presence. However, earnings volatility and high valuation weaken overall health.
📈 Entry Zone & Long-Term Guidance: Current price ₹4,393 is above intrinsic comfort levels. A better entry zone would be closer to ₹4,200–₹4,300, aligning with technical support. Long-term holding is favorable only if earnings stabilize and valuation moderates.
Positive
- ✅ Strong ROCE (24.8%) and ROE (20.0%) indicate efficient capital use.
- ✅ Debt-to-equity at 0.03 reflects a virtually debt-free balance sheet.
- ✅ Institutional support with FII holding up 0.05% and DII holding up 0.42%.
Limitation
- ⚠️ P/E (29.4) above industry average (24.1).
- ⚠️ P/B ratio (~6.3) is steep.
- ⚠️ PEG ratio (-16.2) signals poor growth prospects.
Company Negative News
- 📉 Quarterly profit declined from ₹153 Cr. to ₹95.7 Cr.
- 📉 MACD at -99.8 suggests bearish momentum.
Company Positive News
- 📈 RSI at 38.7 indicates oversold levels, suggesting potential rebound.
- 📈 Dividend yield at 2.84% provides steady income for investors.
Industry
- 🏭 Agrochemical industry P/E at 24.1, lower than Bayer CropScience’s valuation.
- 🏭 Sector growth driven by rising demand for crop protection, innovation in agri-tech, and food security initiatives.
Conclusion
🔎 Bayer CropScience is financially strong with high efficiency and debt-free operations but currently overvalued relative to peers. Entry should be considered near ₹4,200–₹4,300. Long-term holding is favorable only if earnings stabilize and valuation cools down.
Would you like me to extend this with a peer comparison or an intrinsic value analysis to refine the investment outlook?